Celgene Settles Off-Label Marketing Case Celgene agreed to pay $280 million to settle a False Claims Act lawsuit brought in California accusing it of promoting two cancer drugs for unapproved uses. Pharmaceutical companies may only promote drugs for their FDA-approved indications even though doctors may legitimately prescribe them for off-label purposes. The False Claims Act...
Medical Malpractice Reform Threatens Individuals The Trump Administration’s budget proposal for 2018 includes another attempt to pass tort reform for medical malpractice lawsuits. We strongly oppose this effort to weaken compensation for injury victims and urge you to inform your elected representatives that you do not support it. The proposal includes a $250,000 cap on...
I spent some time yesterday reviewing the testimony before the Senate Finance Committee a few weeks ago by health care providers and other organizations regarding the need for revisions to the Stark Law. The general substance of the Stark Law is probably familiar to most people in the health care industry but likely not to those...
Federal spending for compounded drugs has exploded recently and there are concerns some portion of the increase is due to fraud or overbilling, according to recent media reports. Last year, we wrote a post about the increase in Tricare fraud among compounding pharmacies. Recent data reports suggests other programs, including Medicare Part D and federal...
The U.S. Government is stepping up enforcement efforts against home health services fraud according to an Office of the Inspector General (OIG) alert recently published. In a separate June 2016 report from OIG, Medicare estimates that it spent approximately $18.4 billion to reimburse more than 11,000 home health agencies. Of that amount, the Medicare Fee-for-Service...
We are pleased to share with you the news from February and March that Young Law Group secured landmark decisions in two large health care fraud lawsuits against Pfizer and Teva and a third in the case against Bayer for Essure where we are co-counsel. The Pfizer Lawsuit The complaint against Pfizer, one of the...
Health care kickbacks continue to be a hot area of whistleblower practice under the False Claims Act in 2016, with two more settlement announcements already this week. A Pennsylvania medical supply company providing masks to suppliers of durable medical equipment (DME) for patients with sleep apnea settled a False Claims Act case today for $34.8...
For years, many pharmaceutical and medical device companies have paid doctors for speaking engagements as well as offered free meals, gifts and entertainment. A new study by ProPublica analyzing drugmaker spending and Medicare prescription data to conclude that these payments and gifts translate into higher patient prescriptions for brand-name drugs. The analysis concludes that physicians...
Another princeling investigation has wrapped up at the Securities and Exchange Commission, although this one didn’t involve suspicions of violations of the Foreign Corrupt Practices Act by an investment bank. Instead, it was mobile technology company Qualcomm that paid $7.5 million to resolve the government probe into bribery of employees of state-owned enterprises in China....
Pfizer announced an agreement in principle to resolve a long running False Claims Act lawsuit against its subsidiary Wyeth for $785 million a few weeks ahead of trial. Wyeth engaged in the conduct at issue from 2001 to 2006 according to the amended complaint. Wyeth was acquired by Pfizer in 2009. The United States intervened...









